Merck Sharp + Dohme Corp.

Eli Lilly and Company

Msd R&d Co., Ltd.

Mds R&d (China) Co., Ltd.

Weiguo Quan

Ping Liu

Liping Wang

Christopher Joseph Sinz

Jiaqiang Cai

Alejandro Crespo

Xiaoxing Du

Rongqiang Liu

John S Debenham

Christina B Madsen-Duggan

Deodialsingh Guiadeen

Jingye Zhou

Vincent Colandrea

Shankaran Kothandaraman

Byron Dubois

Christopher J Sinz

Koc Kan Ho

Joshua G McCoy

Byron Gabriel Dubois

Cristina B Madsen-Duggan

The present invention provides compounds which are of the formula (I) and (II) wherein X is selected from the group consisting of (III) and (IV); R is selected from the group consisting of (V) and (VI); Q is selected from the group consisting of (VII) and (VIII); and (IX) Ris selected from the group consisting of (X) and (XI); or a pharmaceutically acceptable salt thereof, methods for treating obesity, type II diabetes, and compositions. 

Pyrrolidinone compounds

The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

Inhibitors of HIF prolyl hydroxylase

The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

Growing community of inventors

Shanghai, China

Weiguo Quan